Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.46 |
| ▸ | CA2 | P00918 | 9/20 | 0.46 |
| ▸ | CA9 | Q16790 | 7/20 | 0.46 |
| ▸ | CA5A | P35218 | 3/20 | 0.46 |
| ▸ | CA4 | P22748 | 3/20 | 0.40 |
| ▸ | CA7 | P43166 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4007056 | 0.79 | ALDH1A1 (0.40) | CA1CA2CA9CA7KEAP1 | |
| SCHEMBL1501035 | 0.77 | KEAP1 (0.35) | CA1CA2CA9CA4CA7 | |
| SCHEMBL4004862 | 0.77 | ALDH1A1 (0.39) | CA1CA2CA9CA7KEAP1 | |
| SCHEMBL30297591 | 0.76 | CA2 (0.50) | CA1CA2CA9CA5ACA4 | |
| SCHEMBL4789537 | 0.76 | CA2 (0.50) | CA1CA2CA9CA5ACA4 | |
| SCHEMBL4004865 | 0.76 | TSHR (0.39) | CA1CA2CA9CA4CA7 | |
| Hydrochloric Acid SCHEMBL7559869 | 0.74 | CA2 (0.48) | CA1CA2CA9CA5ACA4 | |
| SCHEMBL6380044 | 0.73 | TAAR1 (0.46) | CA1CA2CA9CA5ALMNA | |
| SCHEMBL3601572 | 0.73 | CA1 (0.46) | CA1CA2CA9CA5ACA4 | |
| SCHEMBL8188323 | 0.73 | CA2 (0.46) | CA1CA2CA9CA5ACA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034960-B2 | Process for the synthesis C-2, C-3 substituted N-alkylated indoles useful as cPLA2 inhibitors | PFIZER INC. (US) | 2011-10-11 | — | — | US | disclosed |
| EP-1778629-B1 | PROCESS FOR THE SYNTHESIS C-2, C-3 SUBSTITUTED N-ALKYLATED INDOLES USEFUL AS CPLA2 INHIBITORS | WYETH LLC (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110054189-A1 | Process For The Synthesis C-2, C-3 Substituted N-Alkylated Indoles Useful As CPLA2 Inhibitors | WYETH LLC | 2011-03-03 | — | — | US | disclosed |
| US-7842837-B2 | Process for the synthesis of C-2, C-3 substituted N-alkylated indoles useful as cPLA2 inhibitors | WYETH LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090306428-A1 | Process for the Synthesis of C-2, C-3 Substituted N-Alkylated Indoles Useful as cPLA2 Inhibitors | WYETH LLC | 2009-12-10 | — | — | US | disclosed |
| US-7582772-B2 | Process for the synthesis C-2, C-3 substituted N-alkylated indoles useful as CPLA2 inhibitors | WYETH (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1778629-A1 | PROCESS FOR THE SYNTHESIS C-2, C-3 SUBSTITUTED N-ALKYLATED INDOLES USEFUL AS CPLA2 INHIBITORS | Wyeth (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006023611-A1 | PROCESS FOR THE SYNTHESIS C-2, C-3 SUBSTITUTED N-ALKYLATED INDOLES USEFUL AS CPLA2 INHIBITORS | WYETH (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060041005-A1 | Process for the synthesis C-2, C-3 substituted N-alkylated indoles useful as CPLA2 inhibitors | WYETH (US) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | NR4A1, NR4A2, NR4A3 | CA1 2639/4885CA2 1381/4885CA9 1834/4885 |
| US-20060041005-A1 | Process for the synthesis C-2, C-3 substituted N-alkylated indoles useful as CPLA2 inhibitors | PLA2G4A, PLA2R1, PLA2G12A | CA1 2005/4885CA2 445/4885CA9 2392/4885 |
| US-20110054189-A1 | Process For The Synthesis C-2, C-3 Substituted N-Alkylated Indoles Useful As CPLA2 Inhibitors | PLA2G4A, PLA2G4B, PLA2G1B | CA1 2298/4885CA2 325/4885CA9 2227/4885 |
| US-20090306428-A1 | Process for the Synthesis of C-2, C-3 Substituted N-Alkylated Indoles Useful as cPLA2 Inhibitors | PLA2G4A, PLA2G12A, PLA2R1 | CA1 2210/4885CA2 416/4885CA9 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.